Oxonica, plc, Acquires Nanoplex Technologies, Inc.; Combined Company Will Lead Commercialization of Broad Spectrum of Diagnostic Tools
Dr. Michael Natan, founder of Nanoplex, commented, "Nanoplex's longstanding goal has been to develop valuable products based on our metal particle nanotechnologies, with an emphasis on the diagnostics and brand security markets. Oxonica's leading products, Optisol(TM) and Envirox(TM), are examples of exactly what we want to achieve: novel, best-of-breed, nanotechnology-enabled offerings with a solid IP foundation. Adding Oxonica's management expertise and sales and marketing infrastructure to Nanoplex's IP base and know-how in nanomaterials, bioassays, optical engineering, and software will allow us to develop better products in a shorter time frame and with greater global reach."
“because it compliments our core strength in multiplexed biolabeling while providing us a base from which to develop sales of the Group's product portfolio in the United States. Together, we will address unmet needs within high-growth markets, including healthcare and brand security.”
"The acquisition of Nanoplex," said Oxonica CEO Kevin Matthews, "marks the next step in strengthening Oxonica's market position in advanced diagnostics by creating a unique combination of scientific, manufacturing and business development skills to facilitate the commercialization of next-generation products."
Based in Mountain View, California, Nanoplex is known for its Surface Enhanced Raman Scattering (SERS) nanotags and Nanobarcodes(R) nanoparticles. Based in Oxford, UK, Oxonica has a reputation as a leading developer of commercial, nanotech-enabled products. Combining the two companies will facilitate the development of detection technologies enabling a full spectrum of transformational diagnostic tools that bridge the healthcare market from drug discovery, to the clinical laboratory and point-of-care.
"This is a strategic acquisition for Oxonica," said David Browning, CEO of Oxonica Healthcare, "because it compliments our core strength in multiplexed biolabeling while providing us a base from which to develop sales of the Group's product portfolio in the United States. Together, we will address unmet needs within high-growth markets, including healthcare and brand security."
Under the terms of the acquisition, Michael Natan will be named President of Oxonica, Inc., reporting directly to Kevin Matthews with operational direction from David Browning, CEO of Oxonica Healthcare. Additionally, Nanoplex Chairman Dr. Gordon Ringold will join the Board of Directors of Oxonica, plc.
About Oxonica, plc
Oxonica, plc, is a leading international nanomaterials group with products in the international marketplace. The company is publicly held and trades on the London Stock Exchange's AIM exchange. Oxonica, plc, was spun out of Oxford University in 1999 and currently employs 37 professionals. Oxonica's mission is to develop innovative commercial applications for nanomaterials and has three divisions: Oxonica Energy, Oxonica Healthcare, and Oxonica Materials. For further information, please visit www.oxonica.com.
About Nanoplex Technologies, Inc.
Nanoplex Technologies is developing nanoparticle-based products for life science research, for ultra-sensitive molecular identification and quantitation, and for authentication and tracking applications. The company's goal is to rapidly convert state-of-the-art nanoscience into practical and valuable products. Nanoplex employs 17 professionals and is located in Mountain View, California. For more information see www.nanoplextech.com.